Community-Acquired Pneumonia (CAP)
What's The Outlook For Mycobacterium Avium Complex? - WebMD
More people around the world have nontuberculous mycobacteria (NTM) infections now than in the past. The infection most often comes from a type of NTM known as mycobacterium avium complex (MAC). MAC is often hard to get rid of. You'll most likely need treatment for a year or more to cure it and it sometimes comes back. But your outlook depends on many factors. Here's what you need to know.
How Does Diagnosis Affect My Outlook?Generally, the earlier you get diagnosed with a MAC infection, the better you'll do. But diagnosis often doesn't happen right away. That's because the infection can look like pneumonia or other lung conditions.
But once doctors realize that could be what you have, it's possible to treat. The sooner this happens, the more likely it is that you'll get the right treatment. You'll also be more likely to have a good outcome.
If you're worried you might have MAC, let your doctor know. Signs to watch for include:
You're more likely to have MAC if you have other health conditions affecting your lungs or immune system. But anyone can get it. If you have these symptoms and they aren't going away, see a doctor who specializes in diagnosing and treating lung conditions. A lung or infectious disease specialist also will have more experience treating MAC infections.
How Do Other Health Conditions Affect My Outlook?Most people get exposed to the bacteria that cause MAC infections. You're more likely to get sick from them if you have other health conditions. Your general health and other chronic conditions also will affect your outlook.
Some factors that may affect how you'll do with treatment include other lung conditions such as:
You're also at more risk and may have a worse outlook with MAC infection if you have a weakened immune system due to conditions including:
You also may be at greater risk for the infection and have a worse outlook if you've had a bone marrow, stem cell, or organ transplant. If you have other health conditions or have had a transplant, ask your doctor how this will affect your outlook with MAC.
What Other Factors Affect My Outlook?Doctors often take other conditions and your symptoms into account when deciding to treat MAC. But some of those same factors also can affect your outlook. You may have a worse outlook if you have:
Doctors may consider these factors when they choose to start treatment. But when you have other health conditions, you may not do as well even with treatment.
It's a good idea to talk to your doctors about your outlook and what you should expect from treatment. Treatment can sometimes get rid of the infection for good. But treatment may also help to keep the infection stable even if it doesn't go away. It may also help you with symptoms of the infection.
What Are the Mortality Rates for MAC?One review of studies found that 1 in 4 people with MAC die within 5 years. But the cause of death wasn't necessarily the infection itself, since many people with MAC have other health conditions, too. The risk also varies a lot from one study to the next.
Your risk of a poorer outcome may be greater if you:
Yes. Your outlook will depend on the specific bacteria causing your infection. MAC infections often don't respond as well to antibiotics as other infections do. Your doctor may do tests to find out what type of bacteria is causing your infection. They may also do tests to see how well the bacteria responds to treatment with antibiotics.
If you treat the infection with one antibiotic, the bacteria causing your infection are more likely to develop resistance. Your outlook will improve if you take two or three antibiotics at once. It's a good idea to see a specialist or other doctor with experience treating MAC to make sure you're taking a combination of medicines that's most likely to work. You'll need to treat the infection for at least a year, and often longer, to be sure the infection is gone.
What if the Infection Comes Back?Your doctor will consider the infection cured once there's no sign of it for at least a year. But sometimes the infection goes away and then comes back. If that happens, it could mean that the infection wasn't really gone. The bacteria may have developed resistance to treatment.
Some studies found that infection with MAC recurs up to 50% of the time. Most of the time that's because of a new infection or reinfection. But it's also possible to have a relapse if the bacteria are still there and bounce back after treatment ends. For some people, the infection can become chronic even with treatment.
What Can I Do to Improve My Outlook With MAC?Even if you get rid of the infection, your lungs may still have lasting damage. But taking steps to care for your lungs and general health can help in your recovery and improve your outlook. Here are some tips to help you improve your chances of a good outcome:
To stay on top of your infection, it helps to be informed. Here are some questions you may want to ask your doctor to make sure you're doing all you can to improve your outlook:
Ask The Doctors: MAC Lung Disease Marked By Cough, Fatigue
ERROR: The request could not be satisfiedRequest blocked. We can't connect to the server for this app or website at this time. There might be too much traffic or a configuration error. Try again later, or contact the app or website owner. If you provide content to customers through CloudFront, you can find steps to troubleshoot and help prevent this error by reviewing the CloudFront documentation.
Generated by cloudfront (CloudFront) Request ID: qcBX2LRycIAZRNowqdQnDNxGk8-F9evItxYq4AMoJ4TODhe_JtzlnA==MAC Lung Disease Market Poised For Growth Across The 7MM During The Forecast Period (2025-2034) Amid Rising Prevalence And New Therapeutic Solutions Delveinsight - MENAFN.COM
(MENAFN- PR Newswire)The MAC lung disease market is predicted to grow in the coming years. This growth is mainly driven by the launch of innovative therapies such as MNKD-101, Bedaquiline fumarate (TMC207), and SPR720, among others. Furthermore, the increasing prevalence of MAC lung disease, influenced by host factors like advanced age, COPD, thoracic abnormalities, and environmental exposure to MAC in soil, water, and aerosol-generating activities, is expected to expand the MAC lung disease market potential.
LAS VEGAS, May 20, 2025 /PRNewswire/ -- Mycobacterium avium Complex (MAC) refers to a group of bacteria, primarily Mycobacterium avium and Mycobacterium intracellulare, that are responsible for MAC lung disease. Accurate identification typically requires genetic testing. MAC is the leading cause of nontuberculous mycobacterial (NTM) lung infections in the United States and can affect people of all ages, although it is more common in older adults, postmenopausal women, smokers, and individuals with weakened immune systems or pre-existing lung conditions such as bronchiectasis, COPD, cystic fibrosis, emphysema, or a prior history of tuberculosis.
DelveInsight estimates that in 2023, there were around 119K diagnosed prevalent cases of MAC lung disease across the 7MM, with the United States accounting for approximately 64% of these cases. In 2023, there were an estimated 151K diagnosed prevalent cases of NTM lung disease across the 7MM, with the number expected to rise by 2034.
Treatment for MAC lung disease typically involves a combination of multiple antibiotics, most often including a macrolide (such as azithromycin or clarithromycin), a rifamycin (such as rifampin or rifabutin), and ethambutol . This regimen works by inhibiting protein synthesis, disrupting the bacterial cell wall, and preventing replication of the mycobacteria. Therapy generally continues for 12 to 18 months, depending on the severity of the disease and the pathogen's drug susceptibility.
Supportive therapies play an important role, especially for patients with preexisting lung conditions. Chest physiotherapy, mucolytic agents, and bronchodilators help clear mucus and alleviate airway obstruction. Additionally, devices like positive expiratory pressure (PEP) masks and high-frequency chest wall oscillation (HFCWO) devices can assist in reducing bacterial burden.
Learn more about the MAC lung disease treatment @ New Treatment for MAC Lung Disease
ARIKAYCE is the first FDA-approved therapy specifically for MAC lung disease. It is a once-daily inhaled formulation of amikacin, delivered using Insmed's proprietary PULMOVANCE technology to directly target the lungs while reducing systemic exposure. The treatment is administered through the Lamira Nebulizer System and was granted orphan drug status by the FDA in 2013.
In May 2024, new data from the ARISE study were presented at ATS 2024, highlighting outcomes in MAC lung disease patients who had not previously received antibiotic therapy. ARIKAYCE is approved in the US, European Union, and Japan, and is currently being studied in the Phase III ENCORE trial , which focuses on newly diagnosed or relapsed MAC patients who have not begun antibiotic treatment. Topline results from this study are anticipated in the first quarter of 2026.
Find out more on FDA-approved MAC lung disease drugs @ MAC Lung Disease Treatment Options
The scarcity of FDA-approved therapies for MAC lung disease, with only ARIKAYCE being the only approved option, limits treatment options, complicates management of resistant strains, and highlights the need for new therapies.
MannKind Corporation, Janssen Pharmaceutical, and Spero Therapeutics are progressing through various stages of clinical trials, driving innovation in the MAC lung disease market. This activity is creating a dynamic environment, offering significant opportunities for the MAC lung disease market expansion and growth. Among the emerging therapies, MNKD-101 , a nebulized formulation of clofazimine , is currently in Phase III clinical development and is expected to launch in the market by 2027.
Discover which therapies are expected to grab major MAC lung disease market share @ MAC Lung Disease Market Report
MNKD-101 is a nebulized formulation of clofazimine being developed to treat severe, chronic, and recurrent lung infections, such as nontuberculous mycobacterial lung disease. This inhaled version is anticipated to provide therapeutic benefits over the existing oral form. MannKind is also working on a dry-powder variant using its proprietary Technosphere platform. In May 2024, the U.S. FDA granted Fast Track Designation to MNKD-101 for NTM lung disease, following its earlier designations as an orphan drug and a Qualified Infectious Disease Product (QIDP) .
The FDA approved the Investigational New Drug (IND) application for MNKD-101 in April 2024, paving the way for a Phase III clinical trial. Similarly, Japan's PMDA authorized the Phase III ICoN-1 trial in September 2024, enabling the global trial to move forward.
Bedaquiline fumarate , marketed as SIRTURO , is a diarylquinoline antimycobacterial agent used in combination regimens to treat pulmonary tuberculosis caused by Mycobacterium tuberculosis strains resistant to both rifampin and isoniazid. It is approved for use in adults and children aged 5 years and older, weighing at least 15 kg.
Bedaquiline is currently being studied in a Phase II/III clinical trial as part of a treatment regimen with clarithromycin and ethambutol for adults with treatment-refractory Mycobacterium avium complex lung disease (MAC-LD).
Spero Therapeutics is developing SPR720 , an oral therapy for NTM pulmonary disease. SPR720 is a stable prodrug that is rapidly converted into SPR719, which targets the ATPase subunits of gyrase and topoisomerase, mechanisms distinct from fluoroquinolones. Preclinical data have demonstrated SPR720's broad-spectrum activity against key NTM pathogens such as MAC, M. Kansasii, and M. Abscessus, in both treatment-refractory and treatment-naïve patients. The FDA has granted SPR720 Fast Track status, orphan drug designation, and QIDP designation .
Discover more about drugs for MAC lung disease in development @ MAC Lung Disease Clinical Trials
The anticipated launch of these emerging therapies for MAC lung disease are poised to transform the market landscape in the coming years. As these cutting-edge therapies continue to mature and gain regulatory approval, they are expected to reshape the MAC lung disease market landscape, offering new standards of care and unlocking opportunities for medical innovation and economic growth.
DelveInsight estimates that the market size for MAC lung disease is expected to grow from USD 474 million in the 7MM in 2023 at a significant CAGR by 2034. The market growth across the 7MM is expected to be fueled by the introduction of novel treatments such as MNKD-101, Bedaquiline fumarate (TMC207), and SPR720, among others. Additionally, the rising incidence of MAC lung disease driven by factors like aging populations, COPD, structural lung abnormalities, and exposure to MAC through soil, water, and aerosol-generating activities will likely contribute to an expanding MAC lung disease market opportunity.
DelveInsight's latest published market report, titled as MAC Lung Disease Market Insight, Epidemiology, and Market Forecast – 2034 , will help you to discover which market leader is going to capture the largest market share. The report provides comprehensive insights into the MAC lung disease country-specific treatment guidelines, patient pool analysis, and epidemiology forecast to help understand the key opportunities and assess the market's underlying potential. The MAC lung disease market report proffers epidemiological analysis for the study period 2020–2034 in the 7MM segmented into:
The report provides an edge while developing business strategies by understanding trends shaping and driving the 7MM MAC lung disease market. Highlights include:
Download this MAC lung disease market report to assess the epidemiology forecasts, understand the patient journeys, know KOLs' opinions about the upcoming treatment paradigms, and determine the factors contributing to the shift in the MAC lung disease market. Also, stay abreast of the mitigating factors to improve your market position in the MAC lung disease therapeutic space.
Related Reports
Nontuberculous Mycobacterial Infection Market
Nontuberculous Mycobacterial Infection Market Insights, Epidemiology, and Market Forecast – 2034 report deliver an in-depth understanding of the disease, historical and forecasted epidemiology, market share of the individual therapies, and key NTM infections companies, including AN2 Therapeutics, Mannkind Corporation, Spero Therapeutics, Paratek Pharmaceuticals, Redhill Biopharma, among others.
Nontuberculous Mycobacterial Infection Pipeline
Nontuberculous Mycobacterial Infection Pipeline Insight – 2024 report provides comprehensive insights about the pipeline landscape, pipeline drug profiles, including clinical and non-clinical stage products, and the key nontuberculous mycobacterial infection companies, including MannKind Corporation, Matinas BioPharma, Spero Therapeutics, Crestone, Inc., Vast Therapeutics, among others.
Chronic Obstructive Pulmonary Disease Market
Chronic Obstructive Pulmonary Disease Market Insights, Epidemiology, and Market Forecast – 2034 report deliver an in-depth understanding of the disease, historical and forecasted epidemiology, market share of the individual therapies, and key chronic obstructive pulmonary disease companies, including Genentech, Inc., GlaxoSmithKline, Verona Pharma plc, Regeneron Pharmaceuticals, Sanofi, MedImmune LLC, EpiEndo Pharmaceuticals, Tetherex Pharmaceuticals, AstraZeneca, Chiesi Farmaceutici S.P.A., Synairgen Research Ltd., Mereo Biopharma, Organicell Regenerative Medicine, Pulmotect, Inc., Inmunotek S.L., PULMATRiX, GLENMARK PHARMACEUTICALS LTD, Dimerix Limited, ProterixBio, among others.
Asthma Market
Asthma Market Insights, Epidemiology, and Market Forecast – 2034 report delivers an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the market trends, market drivers, market barriers, and key asthma companies including GlaxoSmithKline, 4D Pharma plc, AstraZeneca, Suzhou Connect Biopharmaceuticals, Avillion, Pearl Therapeutics, ARS Pharmaceuticals, Sinomab, Avalo Therapeutics, Kymab, Sanofi, Cumberland Pharmaceuticals, Genentech, Inc. , among others.
About DelveInsight
DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports pharma companies by providing comprehensive end-to-end solutions to improve their performance. Get hassle-free access to all the healthcare and pharma market research reports through our subscription-based platform PharmDelve .
Contact Us Shruti Thakur[email protected]+14699457679
Logo: g
SOURCE DelveInsight Business Research, LLP
WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE? 440k+Newsrooms &Influencers 9k+Digital MediaOutlets 270k+JournalistsOpted In GET STARTEDMENAFN20052025003732001241ID1109574247
Comments
Post a Comment